Quanta Prepares For Launch Of SC+ Personal Dialysis Machine
The UK company recently finished a pilot trial of the SC+ personal dialysis system in France, as part of its plan to launch it in Europe by the end of 2018 and earn US FDA clearance in 2019.
You may also be interested in...
Quanta Dialysis has signed an agreement with B. Braun to provide support services to Quanta’s patients in the UK. The hemodialysis firm launched its compact hemodialysis device SC+ on the market at the beginning of the year.
The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable healthcare concept.
End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.